<DOC>
	<DOCNO>NCT00360269</DOCNO>
	<brief_summary>The aim study determine atomoxetine treatment combine motivational enhancement therapy effective reduce marijuana use adult individual attention-deficit hyperactivity disorder marijuana dependence .</brief_summary>
	<brief_title>Atomoxetine Treatment ADHD Marijuana Dependence</brief_title>
	<detailed_description>The purpose study determine whether medication atomoxetine , Strattera , plus 3 session counsel help people reduce symptom ADHD help cut back marijuana use . Participation study approximately 12 week medication treatment doctor 's visit week . The first 2 visit consist evaluation determine qualify participate . These visit approximately 2-3 hour long include question past present substance use , psychiatric history , routine physical exam , bloodwork , paper pencil questionnaire marijuana use . Once enrolled study , visit typically 30 minute long , week . The one-on-one counseling session regard marijuana use 1 hour long 3 session throughout study . If qualify study , receive either atomoxetine , placebo ( sugar pill ) . Study participants 50 % chance receive atomoxetine . Atomoxetine non-stimulant , commonly use treat ADHD .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1 . Healthy men woman , 18 65 year age 2 . Meet DSMIV criterion marijuana dependence 3 . Meet DSMIV criterion current ADHD , determine clinical interview confirm semistructured interview Conners ' Adult ADHD Diagnostic Interview DSMIV ( CAARD ; Conners et al , 1999 ) 4 . ADHD symptom severity indicate score 12 great WenderReimherr Adult Attention Deficit Disorder Scale 5 . ADHD symptom must corroborate second informant either current symptom ( significant close friend ) childhood symptom ( parent older sibling ) 6 . All subject agree sign write , IRBapproved inform consent 7 . Subjects must live within 60mile radius Charleston , SC , facilitate study visit compliance 1 . Individuals meet DSMIV dependence substance marijuana exception nicotine caffeine . Dependence nicotine caffeine allow since dependence substance commonly cooccur marijuana dependence exclude individual would compromise study recruitment 2 . Individuals meet DSMIV criterion lifetime history schizophrenia another nonaffective psychotic disorder bipolar disorder , since patient likely take psychotropic medication often require intensive psychiatric care 3 . Individuals meet DSMIV criterion current major depressive disorder eat disorder , since individual likely require treatment psychotropic medication . Subjects may meet criterion minor mood disorder ( dysthymia ) anxiety disorder . The inclusion subject disorder allow commonly coexist among patient marijuana dependence ( Stephens et al , 1993 ) 4 . Individuals present significant suicidal risk 5 . Individuals significant cognitive impairment measure score less 26 MiniMental Status Exam , may unable understand inform consent , comply study protocol , accurately complete assessment 6 . Individuals currently receive stimulant , benzodiazepine , antidepressant antipsychotic medication , medication could confound effect atomoxetine treatment 7 . Individuals currently receive psychotherapy focus reduce marijuana use ADHD symptom , could confound effect atomoxetine treatment . Participation 12step program allow 8 . Pregnant nursing woman , woman refuse use adequate birth control , atomoxetine approve use pregnancy 9 . Individuals without stable housing , contact individual would difficult 10 . Individuals major medical illness ( e.g. , HIV , renal failure , unstable angina , chronic obstructive pulmonary disease , infectious hepatitis ) 11 . Patients hypertension ( define blood pressure great 140/90 measure 3 occasion ) , atomoxetine treatment associate increase blood pressure 12 . Patients evidence hepatic insufficiency , atomoxetine require hepatic metabolism 13 . Patients urinary hesitancy urinary hesitation , atomoxetine associate urinary hesitation clinical trial 14 . Individuals , investigator ' opinion , would able comply study procedure , individual unable reliably present intake appointment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>